{"id":"https://openalex.org/W2331274473","doi":"https://doi.org/10.2337/db16-0107","title":"Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist","display_name":"Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist","alternate_titles":[],"publication_year":2016,"publication_date":"2016-04-05","ids":{"openalex":"https://openalex.org/W2331274473","doi":"https://doi.org/10.2337/db16-0107","mag":"2331274473","pmid":"https://pubmed.ncbi.nlm.nih.gov/27207543"},"language":"en","primary_location":{"id":"doi:10.2337/db16-0107","doi":"https://doi.org/10.2337/db16-0107","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db16-0107","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2331274473"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067359287","display_name":"Michael Albrecht Nauck","orcid":"https://orcid.org/0000-0002-5749-6954","observed_orcids":["https://orcid.org/0000-0002-5749-6954","https://orcid.org/0000-0003-2455-0472"]},"institutions":[{"id":"https://openalex.org/I4210124421","display_name":"Diabeteszentrum Bad Lauterberg","ror":"https://ror.org/02tv28881","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210124421"]},{"id":"https://openalex.org/I4210138993","display_name":"St. Josef-Hospital","ror":"https://ror.org/046vare28","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I2799784675","https://openalex.org/I4210138993","https://openalex.org/I4210153564"]},{"id":"https://openalex.org/I904495901","display_name":"Ruhr University Bochum","ror":"https://ror.org/04tsk2644","country_code":"DE","type":"education","lineage":["https://openalex.org/I904495901"]}],"countries":["DE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Michael A. Nauck","raw_affiliation_strings":["Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany","Division of Diabetology, Medical Department I, St. Josef-Hospital (Ruhr University Bochum), Bochum, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany","institution_ids":["https://openalex.org/I4210124421"]},{"raw_affiliation_string":"Division of Diabetology, Medical Department I, St. Josef-Hospital (Ruhr University Bochum), Bochum, Germany","institution_ids":["https://openalex.org/I4210138993","https://openalex.org/I904495901"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028871830","display_name":"Joachim Kind","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joachim Kind","raw_affiliation_strings":["PAREXEL, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PAREXEL, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024986806","display_name":"L. K\u00f6the","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124421","display_name":"Diabeteszentrum Bad Lauterberg","ror":"https://ror.org/02tv28881","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210124421"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lars D. K\u00f6the","raw_affiliation_strings":["Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany","institution_ids":["https://openalex.org/I4210124421"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085434984","display_name":"Jens Juul Holst","orcid":"https://orcid.org/0000-0001-6853-3805","observed_orcids":["https://orcid.org/0000-0001-6853-3805"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jens J. Holst","raw_affiliation_strings":["Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark","institution_ids":["https://openalex.org/I124055696"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054335526","display_name":"Carolyn Fiona Deacon","orcid":"https://orcid.org/0000-0003-2611-5642","observed_orcids":["https://orcid.org/0000-0003-2611-5642"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]}],"countries":["DK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Carolyn F. Deacon","raw_affiliation_strings":["Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Copenhagen, Denmark","institution_ids":["https://openalex.org/I124055696"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059745171","display_name":"Matthias Broschag","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Matthias Broschag","raw_affiliation_strings":["PAREXEL, Berlin, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PAREXEL, Berlin, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100778852","display_name":"Yan Ling He","orcid":"https://orcid.org/0000-0002-6496-8016","observed_orcids":["https://orcid.org/0000-0002-6496-8016"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yan Ling He","raw_affiliation_strings":["Novartis Institute for BioMedical Research, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institute for BioMedical Research, Cambridge, MA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068834676","display_name":"Lise Kjems","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lise Kjems","raw_affiliation_strings":["Novartis Institute for BioMedical Research, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institute for BioMedical Research, Cambridge, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5066047147","display_name":"James Edward Foley","orcid":"https://orcid.org/0000-0001-6857-1158","observed_orcids":["https://orcid.org/0000-0001-6857-1158"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"James Foley","raw_affiliation_strings":["Novartis Pharmaceuticals, East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, East Hanover, NJ","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5067359287"],"corresponding_institution_ids":["https://openalex.org/I4210124421","https://openalex.org/I4210138993","https://openalex.org/I904495901"],"apc_list":null,"apc_paid":null,"fwci":6.5619,"has_fulltext":false,"cited_by_count":56,"citation_normalized_percentile":{"value":0.97710424,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"65","issue":"8","first_page":"2440","last_page":"2447"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10839","display_name":"Pancreatic function and diabetes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vildagliptin","display_name":"vildagliptin","score":0.9879999756813049},{"id":"https://openalex.org/keywords/dpp-4-inhibition","display_name":"DPP-4 inhibition","score":0.9459999799728394},{"id":"https://openalex.org/keywords/glucagon-like-peptide-1","display_name":"glucagon-like peptide-1","score":0.949999988079071},{"id":"https://openalex.org/keywords/exendin-9-39","display_name":"exendin-9-39","score":0.925000011920929},{"id":"https://openalex.org/keywords/glp-1-receptor-antagonists","display_name":"GLP-1 receptor antagonists","score":0.9350000023841858},{"id":"https://openalex.org/keywords/insulin-secretion","display_name":"insulin secretion","score":0.7799999713897705},{"id":"https://openalex.org/keywords/glucose-dependent-insulinotropic-polypeptide","display_name":"glucose-dependent insulinotropic polypeptide","score":0.9169999957084656},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9670000076293945},{"id":"https://openalex.org/keywords/test-meal","display_name":"test meal","score":0.4880000054836273},{"id":"https://openalex.org/keywords/insulin-secretion-rate","display_name":"insulin secretion rate","score":0.35100001096725464},{"id":"https://openalex.org/keywords/glycemic-response","display_name":"glycemic response","score":0.45500001311302185},{"id":"https://openalex.org/keywords/mediation-analysis","display_name":"mediation analysis","score":0.3089999854564667}],"concepts":[{"id":"https://openalex.org/C2776453732","wikidata":"https://www.wikidata.org/wiki/Q421042","display_name":"Vildagliptin","level":4,"score":0.9970083236694336},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7790544033050537},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7627345323562622},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7446349263191223},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.7309340238571167},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.6929113268852234},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6507683396339417},{"id":"https://openalex.org/C2781469919","wikidata":"https://www.wikidata.org/wiki/Q5279728","display_name":"Dipeptidyl peptidase","level":3,"score":0.574548602104187},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5409532189369202},{"id":"https://openalex.org/C2778345441","wikidata":"https://www.wikidata.org/wiki/Q6460735","display_name":"Meal","level":2,"score":0.5095901489257812},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.15701082348823547},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.12772667407989502},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.07483822107315063},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000077597","descriptor_name":"Vildagliptin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000218","descriptor_name":"Adamantane","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005746","descriptor_name":"Gastric Emptying","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005749","descriptor_name":"Gastric Inhibitory Polypeptide","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D009570","descriptor_name":"Nitriles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D011759","descriptor_name":"Pyrrolidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.2337/db16-0107","doi":"https://doi.org/10.2337/db16-0107","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db16-0107","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},{"id":"pmid:27207543","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/27207543","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"Controlled Clinical Trial"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/aaaa7c83-ab29-4907-a5f7-4bea883a7bdc","doi":null,"is_oa":false,"landing_page_url":"https://curis.ku.dk/portal/da/publications/quantification-of-the-contribution-of-glp1-to-mediating-insulinotropic-effects-of-dpp4-inhibition-with-vildagliptin-in-healthy-subjects-and-type-2diabetic-patients-using-exendin-939-as-a-glp1-receptor-antagonist(aaaa7c83-ab29-4907-a5f7-4bea883a7bdc).html","pdf_url":null,"source":{"id":"https://openalex.org/S4306401983","display_name":"Research at the University of Copenhagen (University of Copenhagen)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I124055696","host_organization_name":"University of Copenhagen","host_organization_lineage":["https://openalex.org/I124055696"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Nauck, M A, Kind, J, K\u00f6the, L D, Holst, J J, Deacon, C F, Broschag, M, He, YL, Kjems, L & Foley, J 2016, 'Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and type 2-diabetic patients using exendin [9-39] as a GLP-1 receptor antagonist.', Diabetes, vol. 65, no. 8, pp. 2440-2447. https://doi.org/10.2337/db16-0107","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1909310469","https://openalex.org/W1969228291","https://openalex.org/W1969932276","https://openalex.org/W1975591028","https://openalex.org/W1980066993","https://openalex.org/W1986607113","https://openalex.org/W2031468509","https://openalex.org/W2036167841","https://openalex.org/W2037839438","https://openalex.org/W2054185381","https://openalex.org/W2054649558","https://openalex.org/W2059428929","https://openalex.org/W2067710447","https://openalex.org/W2082420583","https://openalex.org/W2093542979","https://openalex.org/W2103923632","https://openalex.org/W2111242088","https://openalex.org/W2115780192","https://openalex.org/W2117891623","https://openalex.org/W2134947605","https://openalex.org/W2141390547","https://openalex.org/W2142903571","https://openalex.org/W2146581079","https://openalex.org/W2146850822","https://openalex.org/W2148416335","https://openalex.org/W2155486681"],"related_works":["https://openalex.org/W2006612490","https://openalex.org/W2146085551","https://openalex.org/W2148416335","https://openalex.org/W2171046854","https://openalex.org/W2000083483","https://openalex.org/W2314970057","https://openalex.org/W1970498822","https://openalex.org/W1976403800","https://openalex.org/W2163984033"],"abstract_inverted_index":{"We":[0],"quantified":[1],"the":[2,10,22,91,94,97,115,166,194,207],"contribution":[3],"of":[4,9,13,83,93,100,123,193,210],"GLP-1":[5,23,125],"as":[6],"a":[7,79],"mediator":[8],"therapeutic":[11,208],"effects":[12,209],"dipeptidyl":[14],"peptidase":[15],"4":[16,112],"(DPP-4)":[17],"inhibition":[18],"(vildagliptin)":[19],"by":[20,145],"using":[21],"receptor":[24],"antagonist":[25],"exendin":[26,84,154,171],"[9-39]":[27,155,172],"in":[28,35,54,137,147,165],"patients":[29,39,148],"with":[30,40,57,78,149,170],"type":[31,41,150],"2":[32,42,151],"diabetes":[33,43],"and":[34,44,47,74,77,107,126,130,153,186],"healthy":[36,49,138],"subjects.":[37,139],"Thirty-two":[38],"29":[45],"age-":[46],"weight-matched":[48],"control":[50],"subjects":[51],"were":[52,70],"treated":[53],"randomized":[55],"order":[56],"100":[58],"mg":[59],"once":[60],"daily":[61],"vildagliptin":[62,177],"or":[63],"placebo":[64,181],"for":[65],"10":[66],"days.":[67],"Meal":[68],"tests":[69],"performed":[71],"(days":[72],"9":[73],"10)":[75],"without":[76,134],"high-dose":[80],"intravenous":[81],"infusion":[82],"[9-39].":[85],"The":[86,162],"main":[87],"end":[88],"point":[89],"was":[90,173,187],"ratio":[92,144,168],"areas":[95],"under":[96],"curve":[98],"(AUCs)":[99],"integrated":[101],"insulin":[102],"secretion":[103],"rates":[104],"(total":[105,109],"AUCISR)":[106],"glucose":[108,132],"AUCglucose)":[110],"over":[111],"h":[113],"after":[114,176,180],"meal.":[116],"Vildagliptin":[117,140],"treatment":[118,178,182],"more":[119],"than":[120,179],"doubled":[121],"responses":[122,133],"intact":[124],"glucose-dependent":[127],"insulinotropic":[128],"polypeptide":[129],"lowered":[131],"changing":[135],"AUCISR/AUCglucose":[136,167],"significantly":[141,174,205],"increased":[142],"this":[143],"10.5%":[146],"diabetes,":[152],"reduced":[156],"it":[157],"(both":[158],"P":[159],"<":[160],"0.0001).":[161],"percentage":[163],"reduction":[164],"achieved":[169],"smaller":[175],"(P":[183],"=":[184],"0.026)":[185],"equivalent":[188],"to":[189,197,203,206],"47":[190],"\u00b1":[191],"5%":[192],"increments":[195],"due":[196],"vildagliptin.":[198],"Thus,":[199],"other":[200],"mediators":[201],"appear":[202],"contribute":[204],"DPP-4":[211],"inhibition.":[212]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2331274473","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":15},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":4}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2016-06-24T00:00:00"}
